Company intelligence / Profile preview
Pet Pharm Biotech
New Taipei City, Taiwanpetpharmbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pet Pharm Biotech produces commercial radiopharmaceuticals used in diagnostic imaging for oncology and neurology. Products include FDG for PET scans (oncology/metabolic imaging), NeuraCeq (FBB) for brain amyloid imaging, NaF for bone imaging, and 131I capsules for thyroid therapy and diagnosis. These are approved and on the market in Taiwan, with high-quality GMP manufacturing and some clinical data supporting their utility in various cancers and neurological diseases.
- Therapeutic areas
- CardiovascularOncologyNeurologyEndocrinology
- Modalities
- Radiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Pet Pharm Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pet Pharm Biotech.